Advertisement
News
Advertisement

Boehringer Ingelheim launches ‘Lean-to-Clinic’ program for fast drug product supply

Thu, 01/26/2012 - 3:25am
Boehringer Ingelheim

Ingelheim/Germany, 26 January 2012 – Boehringer Ingelheim has expanded its biopharmaceutical cell line development services and provides drug substance as fast as 13 months at competitive prices. The novel program is called ‘Lean-to-Clinic’ and leverages Boehringer Ingelheim’s established platforms and processes for the production of monoclonal antibodies using the proprietary BI-HEX® high expression system.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading